Symbion Health Ltd.
https://www.symbion.com.au/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Symbion Health Ltd.
Shire/TKT: The Price of Diversification
Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.
Pliva: Two Steps Forward, One Step Back?
After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.
Biogenerics: A Step Closer
Progress on biogenerics inches along, as evidenced by deal between Barr Pharmaceuticals and PLIVA giving Barr rights to market Pliva's version of G-CSF in North America, and by the recent well-attended FDA workshop on follow-on proteins (FOPs). Barr/PlLIVA, the first company/company deal in this field in months indicates that companies still see opportunity despite last year's regulatory setbacks. The FDA workshop, while far from conclusive, hinted at a softening of positions by both opponents and proponents of biogenerics; at least they're talking the same language.
Company Information
- Industry
- Laboratory Testing Services
- Pharmaceuticals
- Services
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Maybe Group
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice